NASDAQ:RDUS - Radius Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$28.75 -0.52 (-1.78 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$29.14
Today's Range$28.57 - $29.24
52-Week Range$24.66 - $48.97
Volume28,835 shs
Average Volume625,463 shs
Market Capitalization$1.33 billion
P/E Ratio-4.96
Dividend YieldN/A
Radius Health logoRadius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.87
Current Ratio6.55
Quick Ratio6.41


Trailing P/E Ratio-4.96
Forward P/E Ratio-5.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.11 million
Price / Sales59.11
Cash FlowN/A
Price / CashN/A
Book Value$5.43 per share
Price / Book5.29


EPS (Most Recent Fiscal Year)($5.80)
Net Income$-254,230,000.00
Net Margins-706.11%
Return on Equity-108.95%
Return on Assets-64.23%


Outstanding Shares45,460,000
Market Cap$1,330.58

The Truth About Cryptocurrencies

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) posted its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($1.37) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.46) by $0.09. The biopharmaceutical company earned $14.50 million during the quarter, compared to analyst estimates of $13.80 million. Radius Health had a negative net margin of 706.11% and a negative return on equity of 108.95%. During the same period in the previous year, the business posted ($1.32) EPS. View Radius Health's Earnings History.

What price target have analysts set for RDUS?

9 equities research analysts have issued 1-year target prices for Radius Health's stock. Their forecasts range from $31.00 to $85.00. On average, they anticipate Radius Health's stock price to reach $54.25 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View Analyst Ratings for Radius Health.

What is the consensus analysts' recommendation for Radius Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)
  • 2. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Forteo and Prolia. Further, the company suffered a setback when the CHMP issued a negative trend vote on the benefit-risk balance for the MAA for abaloparatide-SC in an oral explanation. The CHMP will therefore adopt a negative opinion on the same. The delay in getting approval in Europe is disappointing given the market potential. The company’s shares have underperformed the industry in the last three months. Meanwhile, estimates are stable ahead of the first-quarter results (scheduled on May 8)." (5/2/2018)
  • 3. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Dr. Gregory Williams Ph.D., MBA, Chief Devel. Officer (Age 59)
  • Dr. Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 64)
  • Mr. Brian Nicholas Harvey, Advisor (Age 57)
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 58)
  • Dr. Stavros C. Manolagas M.D., Ph.D., Co-Founder and Member of the Scientific Advisory Board

Has Radius Health been receiving favorable news coverage?

Media headlines about RDUS stock have been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Radius Health earned a news sentiment score of -0.01 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $28.75.

How big of a company is Radius Health?

Radius Health has a market capitalization of $1.33 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

MarketBeat Community Rating for Radius Health (NASDAQ RDUS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  583
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.